Use LEFT and RIGHT arrow keys to navigate between flashcards;
Use UP and DOWN arrow keys to flip the card;
H to show hint;
A reads text to speech;
158 Cards in this Set
- Front
- Back
Selective toxicity of antiviral drugs depends on?
|
greater susceptibility of viral enzymes to their inhibitory actions than host cell enzymes
|
|
Why combination drug therapy?
|
greater clinical effectiveness and prevention, or delay, of emergence of resistance
|
|
Most drugs active against herpes viruses are?
|
antimetabolites bioactivated by viral or host cell kinases to form compounds that inhibit viral DNA polymerases
|
|
MOA of acyclovir
|
guanosine analog active against HSV 1/2 and VZV
|
|
Acyclovir activated to form what
|
acyclovir triphosphate which interferes with viral synthesis
|
|
Two ways in which Acyclovir interferes with viral synthesis?
|
competitive substrate for DNA polymerase, and chain termination after incorporation into viral DNA
|
|
HSV resistance to Acyclovir?
|
changes in viral DNA polymerase
|
|
HSV resistant strains lack?
|
thymidine kinase-enzyme involved in initial viral-specific phosphorylation of acyclovir
|
|
pharmacokinetics of Acylcovir
|
topical, oral, IV
short half life (oral needs multiple daily doses) |
|
Elimination of Acylcovir
|
renal excretion
|
|
Clinical uses of acyclovir?
|
oral-mucocutaneous and genital herpes
IV-severe herpes disease including encephalitis, and neonatal infection |
|
Tox of acyclovir?
|
oral: GI distress and headache
IV: delirium, tremor, seizures, hypotension, nephrotoxicity |
|
Valacyclovir
|
prodrug converted to acyclovir by hepatic metabolism; reaches plasma levels 3-5x acyclovir and has longer duration of action
|
|
Penciclovir
|
activated by viral thymidine kinase and the triphosphate form inhibits DNA polymerase (no chain termination)
|
|
Famciclovir
|
prodrug of penciclovir (converted in liver)
|
|
Docosanol
|
aliphatic alcohol that inhibits fusion between HSV envelope and plasma membranes; prevents viral entry and replication; shortens healing time when used topically
|
|
Ganciclovir MOA
|
guanine derivative, triphosphorylated to form a nucleotide that inhibits DNA polymerases of CMV and HSV and causes chain termination
|
|
First phosphorylation of ganciclovir catalyzed by?
|
virus-specific enzymes in CMV and HSV infected cells
|
|
CMV resistance to ganciclovir?
|
mutations in genes that code for activating viral phosphotransferase and viral DNA polymerase
|
|
Pharmacokinetics of ganciclovir
|
IV-good penetration including eye and CNS
|
|
Elimination of ganciclovir?
|
renal elimination in direct proportion to creatinine clearance; oral bioavailability <10%
|
|
Valgancivlovir
|
prodrug of ganciclovir; high oral bioavailability; decreased use of IV ganciclovir for end-organ CMV disease
|
|
Clinical uses of ganciclovir?
|
prophylaxis and treatment of CMV retinitis
|
|
Tox of ganciclovir?
|
leukopenia, thrombocytopenia, mucositis, hepatic dysfunction, seizures
|
|
Ganciclovir with zidovudine?
|
severe neurtropenia
|
|
Cidofovir MOA
|
activated by host cell kinases and the activated diphosphate inhibits DNA polymerase of HSV, CMV, adenovirus, and HPV; active against ganciclovir and acyclovir resistant strains
|
|
Pharmacokinetics of cidofovir?
|
given IV and renal elimination
|
|
Clinical use of cidofovir?
|
CMV retinitis, mucocutaneous HSV, genital warts
|
|
Tox of cidofovir?
|
nephrotoxicity
|
|
Foscarnet
|
phosphonoformate derivative that does not require phosphorylation for antiviral activity
|
|
Foscarnet MOA?
|
inhibits viral RNA polymerase, DNA polymerase, and HIV reverse transcriptase
|
|
Resistance to foscarnet?
|
point mutations in DNA polymerase gene
|
|
Pharmacokinetics of foscanet?
|
IV; good penetration including CNS, renal elimination in direct proportion to creatinine clearance
|
|
Clinical use of foscarnet?
|
alternative for prophylaxis and treatment of CMV infections; has activity against ganciclovir-resistant strains; inhibits herpes DNA polymerase in acyclovir-resistant strains
|
|
Tox of foscarnet?
|
hephrotoxicity (30%), electrolyte imbalance (hypocalemia), GU ulceration, CNS effects
|
|
Elimination of ganciclovir?
|
renal elimination in direct proportion to creatinine clearance; oral bioavailability <10%
|
|
Vidarabine
|
adenine analog with activity against HSV, VZV, CMV
|
|
Valgancivlovir
|
prodrug of ganciclovir; high oral bioavailability; decreased use of IV ganciclovir for end-organ CMV disease
|
|
Clinical uses of vidarabine?
|
Topically against HSV keratitis
|
|
Clinical uses of ganciclovir?
|
prophylaxis and treatment of CMV retinitis
|
|
Tox of ganciclovir?
|
leukopenia, thrombocytopenia, mucositis, hepatic dysfunction, seizures
|
|
Tox of vidarabine?
|
GI irritation, paresthesias, tremor, convulsions, hepatic dysfunction
|
|
Ganciclovir with zidovudine?
|
severe neurtropenia
|
|
Two drugs used topically in herpes keratitis
|
idoxuridine and trifluridine; pyrimidine analogs (too toxic for systemic use)
|
|
Cidofovir MOA
|
activated by host cell kinases and the activated diphosphate inhibits DNA polymerase of HSV, CMV, adenovirus, and HPV; active against ganciclovir and acyclovir resistant strains
|
|
Fomivirsen
|
antisense oligonucleotide that binds to mRNA of CMV; inhibits early protein synthesis
|
|
Pharmacokinetics of cidofovir?
|
given IV and renal elimination
|
|
Clinical use of cidofovir?
|
CMV retinitis, mucocutaneous HSV, genital warts
|
|
Tox of cidofovir?
|
nephrotoxicity
|
|
Foscarnet
|
phosphonoformate derivative that does not require phosphorylation for antiviral activity
|
|
Tox of fomivirsen
|
iritis, vitreitis, increased IOP, changes in vision
|
|
primary drugs effective against HIV
|
antimetabolite inhibitors of viral reverse transcriptase and inhibitors of viral aspartate protease
|
|
Normal combination (3 drugs?)
|
nucleoside reverse transcriptase inhibitors, inhibitors of HIV protease
|
|
NRTIs
|
prodrugs converted by host cell kinases to triphosphates, which competitively inhibit binding of natural nucleotides to dNTP-binding site of RT but also terminate chains via insertion into growing DNA chain
|
|
Why is attachment of the next nucleotide impossible?
|
NRTIs lack a 3'-hydroxyl group on the ribose ring
|
|
Resistance to NRTIs via?
|
mutations in the pol gene
|
|
Abacavir
|
guanosine analog; good oral bioavailability and an intracellular half-life of 12-24 hr; slow resistance
|
|
Side effect of abacavir and frequency?
|
Hypersensitivity reactions (sometimes fatal); 5% HIV patients
|
|
Didanosine (ddI) reduced oral bioavailability?
|
food and chelating agents
|
|
ddI elimination
|
kidney
|
|
other ddI tox?
|
peripheral neuropathy, diarrhea, hepatic dysfunction, hyperuricemia, CNS effects
|
|
Emtricitabine
|
good oral bioavailability; renal elimination with long half-life (once-daily dosing);
|
|
Contraindications of emtricitabine?
|
pregnancy and young children, patients with hepatic or renal dysfunction because contains propylene glycol
|
|
adverse effects of emtricitabine?
|
asthenia, GI distress, headache, hyperpigmentation of the palms/soles
|
|
Lamivudine (3TC)
|
80% oral bioavailability; eliminated almost exclusively by the kidney
|
|
Lamivudine also effective in?
|
HBV
|
|
Stavudine (d4T)
|
good oral bioavailability and good penetration including CNS;
|
|
Tox of stavudine and exacerbated by?
|
peripheral neuropathy; coadministration of didanosine or zalcitabine
|
|
What side effect occurs more often with stavudine than other NRTIs?
|
hepatic steatosis
|
|
Tenofovir
|
nucleotide; also has activity against HBV; oral bioavailability= 25-40%; intracellular half life >60 hrs; renal elimination
|
|
Adverse effects of tenofovir?
|
GI distress, asthenia, headache; rare acute renal failure and Fanconi's syndrome
|
|
Zalcitabine (ddC)
|
high oral bioavailability; renal elimination
|
|
Side effects of zalcitabine (ddC)
|
pancreatitis, esophageal ulceration, stomatitis, arthralgias
|
|
Zidovudine (ZDV) [formerly AZT]
|
active orally and distributed to most tissues including CNS;
|
|
elimination of ZDV
|
hepatic metabolism to glucuronides and renal excretion
|
|
primary toxicity of ZDV
|
bone marrow suppression leading to anemia and neutropenia
|
|
other tox of ZDV
|
thrombocytopenia, headaches, myalgia, acute cholestatic hepatitis, agitation, insomnia
|
|
drugs that increase plasma levels of zidovudine
|
azole antifungals and protease inhibitors
|
|
drug that increases clearance of ZDV
|
rifampin
|
|
Global side effects of NRTIs
|
lactic acidemia and severe hepatomegaly with steatosis
|
|
Adverse effects of tenofovir?
|
GI distress, asthenia, headache; rare acute renal failure and Fanconi's syndrome
|
|
Zalcitabine (ddC)
|
high oral bioavailability; renal elimination
|
|
Side effects of zalcitabine (ddC)
|
pancreatitis, esophageal ulceration, stomatitis, arthralgias
|
|
Zidovudine (ZDV) [formerly AZT]
|
active orally and distributed to most tissues including CNS;
|
|
elimination of ZDV
|
hepatic metabolism to glucuronides and renal excretion
|
|
primary toxicity of ZDV
|
bone marrow suppression leading to anemia and neutropenia
|
|
other tox of ZDV
|
thrombocytopenia, headaches, myalgia, acute cholestatic hepatitis, agitation, insomnia
|
|
drugs that increase plasma levels of zidovudine
|
azole antifungals and protease inhibitors
|
|
drug that increases clearance of ZDV
|
rifampin
|
|
Global side effects of NRTIs
|
lactic acidemia and severe hepatomegaly with steatosis
|
|
MOA of etravirine
|
substrate and inducer of CYP3A4 and inhibitor of CYP2C9 and CYP2C19
|
|
Nevirapine
|
good oral bioavailability; metabolized by hepativ CYP3A4
|
|
Use of nevirapine
|
effective in preventing HIV vertical transmission when given as single dose to mothers at the onset of labor
|
|
Side effect of nevirapine
|
hypersensitivity (15-20%); Stevens-Johnson syndrome, epidermal necrolysis
|
|
Drugs that increase nevirapine blood levels?
|
cimetidine and macrolides
|
|
Drugs that decrease nevirapine blood levels?
|
rifampin (enzyme inducers)
|
|
pol gene encodes?
|
aspartate protease essential for assembly of infectious HIV virions
|
|
resistance to protease inhibitors via?
|
point mutations in the pol gene
|
|
MOA of PIs
|
substrates and inhibitors of CYP3A4; ritonavir with most pronounced effect
|
|
Atazanavir
|
oral absorption requires acidic environment (no antacid ingestion)
|
|
elimiation of atazanavir?
|
biliary
|
|
adverse effects of atazanavir?
|
GI distress, peripheral neuropathy, skin rash, hyperbilirubinemia
*prolongation of QT interval at high doses |
|
Darunavir
|
newer drug in combo with ritanovir in treatment of patients with resistance to other PIs; substrate of CYP3A4
|
|
Darunavir special consideration?
|
contains a sulfonamide moiety; cross reaction with sulfonamide allergy
|
|
fosamprenavir
|
prodrug forming amprenavir via hydrolysis in GI tract; used in combination with lose-dose ritonavir
|
|
absorption and metabolism of fosamprenavir?
|
absorption impeded by fatty foods; hepatic metabolisms
|
|
Cross allergenicity of fosamprenavir?
|
sulfonamides
|
|
indinavir
|
good oral bioavailability except in presence of food
|
|
indinavir metabolism?
|
hepatic and 10% renal
|
|
adverse effects of indinavir?
|
nausea, diarrhea, thrombocytopenia, hyperbilirubinemia, hephrolithiasis
|
|
reduction of renal damage with indinavir
|
hydration
|
|
more common with indinavir than other PIs?
|
insulin resistance
|
|
Drugs that increase serum levels of indinavir?
|
azole antifungals
|
|
Drugs that decrease serum levels of indinavir?
|
rifamycins
|
|
Indinavir increases the serum levels of?
|
antihistamines, benzodiazepines, rifampin
|
|
Nelfinavir
|
increased oral absorption in the presence of food; hepatic metabolism via CYP3A4, short half life
|
|
When is nelfinavir favored?
|
pregnancy
|
|
Ritonavir
|
good oral bioavailability; should be taken with meals
|
|
Clearance of ritonavir?
|
hepatic
|
|
most common adverse effects of ritonavir
|
GI irritation and bitter taste; also paresthesias and elevations of hepatic aminotransferases and triglycerides in plasma
|
|
drugs that reduce serum levels of ritonavir?
|
anticonvulsants, rifamycins (drugs that increase the activity of CYP3A4)
|
|
drugs that increase serum levels of ritonavir?
|
azole antifungals, cimetidine, erythromycin (drugs that inhibit CYP3A4)
|
|
Ritonavir inhibits metabolism of?
|
erythromycin, dronabinol, ketoconazole, prednisone, rifampin, saquinavir
|
|
rationale for PI combinations that include ritonavir?
|
subtherapeutic doses inhibit CYP3A-mediated metabolism of other protease inhibitors; permits use of lower doses of other PIs
|
|
Saquinavir
|
extensive first-pass metabolism
|
|
Tipranavir
|
treatment-experienced patients with resistance to other PIs; substrate and inducer of CYP3A4 and induces P-glycoprotein transporters
|
|
Association of tipranavir and side effects?
|
increased blood levels of statins, increasing risk for myopathy and rhabdomyolysis
|
|
PI effect on carbohydrate and lipid metabolism
|
hyperglycemia and insulin resistance or hyperlipidemia (30-50%)
|
|
Maraviroc
|
Entry inhibitor-target is CCR5 (human protein); blocks viral attachment
|
|
Enfuvirtide MOA
|
peptide that binds to the gp41 subunit, preventing the conformational changes required for the fusion of the viral and cellular membranes
|
|
resistance to enfuvirtide occurs via?
|
mutation in env gene
|
|
administration of enfuvirtide
|
subcutaneously in combination with other anti-HIV drugs
|
|
metabolism of enfuvirtide
|
via hydrolysis and does not involved cytochrome P450 system
|
|
Anti-Influenenza agents
|
amantadine and rimantadine
|
|
amantadine and rimantadine MOA
|
inhibit and early step in replication of the influenza A virus; prevent "uncoating" by binding to a protein M2
|
|
Function of M2 protein
|
proton ion channel required at the onset of infection to permit acidification of the virus core--> activates viral RNA transcriptase
|
|
Clinical uses of A and R?
|
prophylactic against influenza A
|
|
toxic effects of A and R?
|
Gi irritation, dizziness, ataxia, slurred speech
|
|
MOA of Oseltamivir and Zanamivir
|
inhibitors of neuraminidases produced by influenza A and B; also currently active against H3N2 and H1N1 strains
|
|
function of neuraminidases
|
cleave sialic acid residues from viral proteins and surface proteins of infected cells; promote virion release
|
|
Clinical use of oseltamivir and zanamivir
|
O: prodrug used orally, activated int he gut and liver
Z: intransally decrease the time of alleviation of symptoms after onset |
|
difference between agents of HBV and HCV
|
HBV: goal is suppressive
HCV: goal is viral eradication |
|
INF-a
|
cytokine that increases activity of JAKs
|
|
How do JAKs work?
|
phosphorylate signal transducers and activators of transcription (STATs) to increase the formation of antiviral proteins
|
|
Clinical uses of INF-a
|
chronic HBV; in combination with ribavirin for reduction in progression from acute to chronic HCV
|
|
other uses of INF-a
|
kaposi's sarcoma, papillomatosis, genital warts
|
|
Toxicity of INF-a
|
Gi irritation, flulike syndrome, neutropenia, alopecia, hearing loss, thyroid dysfunction, mental confusion, depression
|
|
Contraindications for INF-a
|
autoimmune disease, cardiac arrhythmias, pregnancy
|
|
Adeforvir Dipivoxil MOA
|
prodrug of adefovir; after being phosphorylated competitively inhibits HBV DNA polymerase and results in chain termination
|
|
Pharmacokinetics and clinical use
|
eliminated by the kidney; suppresses HBV replication and improves liver histology and fibrosis; active against lamivudine-resistant strains of HBV
|
|
Entecavir
|
guanosine nucleoside that inhibits HBV DNA polymerase; cross resistance with lamivudine
|
|
Lamivudine
|
nucleoside inhibitor of HIV reverse transcriptase; longer intracellular half-life in HBV-infected cells
|
|
Monotherapy of lamivudine for HBV
|
rapid suppression of replication and remarkably nontoxic; 20% increase in resistance each year
|
|
Ribavirin MOA
|
inhibits replication of wide range of DNA and RNA viruses (Influenza A and B, parainfluenza, RSV, paramyxoviruses, HCV, HIV); inhibits guanosine triphosphate formation, prevents capping of viral mRNA, can block RNA-dependent RNA polymerases
|
|
Pharmacokinetics of ribavirin
|
effective orally and eliminated via kidney; used adjunctively with IFN-a in chronic HCV
|
|
Early administration (IV) of ribavirin
|
decreases mortality in viral hemorrhagic fevers
|
|
Toxicity of ribavirin
|
dose-dependent hemolytic anemia; conjunctival and bronchial irritation; ABSOLUTELY CONTRAINDICATED IN PREGNANCY
|
|
Telbivudine
|
nucleoside analog; phosphorylated by cellular kinases to triphosphate form (inhibits HBV DNA polymerase)
|